CircuLex Rat NGAL/Lipocalin-2 ELISA Kit

  • Applications
    • ELISA
  • Code # CY-8053
  • Size 96 Assays
  • Price Call for Price


Human neutrophil gelatinase-associated lipocalin (NGAL), also called human lipocalin-2, was originally identified as an associated protein to 92-kDa human neutrophil type IV collagenase, also called gelatinase B or matrix metalloproteinase-9 (MMP-9) (1). The rat ortholog, neu-related lipocalin (NRL) or α2-microglobulin-related protein, was identified as a protein highly overexpressed in mammary cancers. The murine ortholog, called 24p3, 24 kDa superinducible protein (Sip24), or uterocalin, was identified as a protein induced in response to various proliferative signals and is highly expressed in uterine luminal fluids and epithelial cells. Recently, 24p3 has also been implicated in processes as diverse as apoptosis (2) and kidney cell differentiation (3). NGAL, like most lipocalins, is thought to modulate cellular processes by binding to ligand(s) and interacting with specific cell-surface receptors. Evidence for such a mammalian receptor for NGAL has recently been reported (2). One early hypothesis proposed that NGAL has immunomodulatory activity by binding and clearing lipophilic inflammatory mediators (4), such as the neutrophil tripeptide chemoattractant N-formyl-Met-Leu-Phe (5, 6). NGAL is released from the secondary granules of activated neutrophils (1) and plasma levels rise in inflammatory or infective conditions, especially in bacterial infections (7). Thus the level of NGAL in plasma or serum has been proposed as a marker of infection. However, as levels of NGAL may also be raised in neoplastic conditions and renal disorders independently of any infective process, this proposed application should be treated with caution. An early and dramatic upregulation was later observed in rat proximal tubule cells after ischemia-reperfusion injury (8), and raised plasma levels of NGAL were found to be strongly correlated with decreased renal function in patients with renal damage due to systemic vasculitis (9). The results for renal ischemia-reperfusion injury were subsequently confirmed and extended to nephrotoxic agents (10-12). It has been suggested that urinary NGAL levels may serve as an early marker for ischemic renal injury in children after cardiopulmonary bypass (13).
  • Application:
  • Components:
    • Microplate 10X Wash Buffer
    • Dilution Buffer
    • Rat NGAL Standard
    • Biotinylated Detection Antibody
    • HRP conjugated Streptavidin
    • Substrate Reagent , Stop Solution
  • Description:

    The CycLex Research Product CircuLex Rat NGAL/Lipocalin-2 ELISA Kit is used for the quantitative measurement of rat NGAL/Lipocalin-2 in serum, plasma, urine, tissue culture medium and other biological media. It can be used for 96 Assays.

  • Product Type:
    ELISA Kit
  • Research Area:
  • Short Description:

    CircuLex Rat NGAL/Lipocalin-2 ELISA Kit.

  • Size:
    96 Assays
  1. Giasson J, Li GH, Chen Y.; Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non--acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets. 10: 272-82, 2011
  1. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. 1993; Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 268: 10425-32.
  2. Devireddy, L.R., Teodoro, J.G., Richard, F.A. and Green, M.R., 2001; Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 293: 829–834.
  3. Yang, J., Goetz, D., Li, J.-Y., Wang, W., Mori, K., Setlik, D., Du, T., Erdjument-Bromage, H., Tempst, P., Strong, R. and Barasch, J., 2002; Iron delivery pathway mediated by a lipocalin. Mol. Cell 10: 1045–1056.
  4. Bundgaard, J.R., Sengelov, H., Borregaard, N. and Kjeldsen, L., 1994; Molecular cloning and expression of a cDNA encoding NGAL: a lipocalin expressed in human neutrophils. BBRC. 202: 1468–1475.
  5. Chu, S.T., Lin, H.J. and Chen, Y.H., 1997. Complex formation between a formyl peptide and 24p3 protein with a blocked N-terminus of pyroglutamate. J. Pept. Res. 49: 582–585. 6. Sengelov, H., Boulay, F., Kjeldsen, L. and Borregaard, N., 1994. Subcellular localization and translocation of the receptor for N-formylmethionyl-leucyl-phenylalanine in human neutrophils. Biochem. J. 299: 473–479.
  6. Xu SY, Pauksen K, Venge P. 1995: Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections. Scand J Clin Lab Invest 55: 125-131.
  7. Matthaeus T, Schulze-Lohoff E, Ichimura T, Weber M, Andreucci M, Park KM, Alessandrini A, Bonventre JV. 2001; Co-regulation of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the postischemic rat kidney. J Am Soc Nephrol 12: 787A.
  8. Ohlsson S, Wieslander J, Segelmark M. 2003; Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission. Clin Exp Immunol 131: 528-535.
  9. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. 2003); Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543.
  10. Amin RP, Vickers AE, Sistare F, Thompson KL, Roman RJ, Lawton M, Kramer J, Hamadeh HK, Collins J, Grissom S, Bennett L, Tucker CJ, Wild S, Kind C, Oreffo V, Davis JW 2nd, Curtiss S, Naciff JM, Cunningham M, Tennant R, Stevens J, Car B, Bertram TA, Afshari CA. 2004; Identification of putative gene based markers of renal toxicity. Environ Health Perspect 112: 465-479.
  11. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. 2004; Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24: 307-315.
  12. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. 2005; Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365: 1231-1238.